Clinical trials: Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF
This open-label, single arm study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with active, moderate to severe rheumatoid arthritis who have an inadequate response to disease-modifying…
- Trial name
- NCT01326962
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 28 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan
The study is designed as a prospective, observational study to assess the effect of adalimumab on health-related quality of life (QoL) and work productivity in patients with rheumatoid arthritis (RA) in Taiwan.
- Trial name
- ROCKI (NCT02616380)
- Volunteers
- 100 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
This prospective, multi-center, observational study will assess the efficacy and safety of treatment in patients who are treated with a TNF Inhibitor or RoActemra/Actemra (tocilizumab) as the first biologic therapy.
- Trial name
- NCT01543503
- Where
- 154 sites in Argentina, Belgium and 14 more
- Volunteers
- 1,225 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
This study will evaluate the efficacy and safety of ocrelizumab, compared to placebo, in patients with active rheumatoid arthritis who have an inadequate response to methotrexate therapy.
- Trial name
- FEATURE (NCT00673920)
- Testing
- Methotrexate, Ocrelizumab
- Volunteers
- 314 people
- Sponsor
- Genentech, Inc.
Healthy Participants, Rheumatoid Arthritis (RA) Prevention
Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
The purpose of this study is to determine if hydroxychloroquine (HCQ) is safe and effective for the prevention of future onset of rheumatoid arthritis (RA) in individuals who have elevations of an autoantibody, anti-cyclic…
- Trial name
- StopRA (NCT02603146)
- Testing
- Hydroxychloroquine
- Where
- 14 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
The purpose of this study is to compare the safety and efficacy of multiple doses of PF-04171327, an experimental glucocorticoid drug, to prednisone at 5 mg or 10 mg and placebo in the treatment of rheumatoid arthritis.
- Trial name
- NCT01393639
- Testing
- PF-04171327, prednisone
- Where
- 93 sites in United States, Bulgaria and 16 more
- Volunteers
- 323 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy
This observational study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in monotherapy in routine clinical practice in participants with rheumatoid arthritis.
- Trial name
- NCT01705730
- Testing
- tocilizumab
- Where
- 17 sites in Belgium
- Volunteers
- 71 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis
This 2-arm study assessed the safety and efficacy of tocilizumab versus placebo, both in combination with disease modifying antirheumatic drugs (DMARDs), in regard to reduction in signs and symptoms, in patients with moderate to…
- Trial name
- ROSE (NCT00531817)
- Testing
- Tocilizumab, Permitted DMARDs
- Where
- 157 sites in United States, Puerto Rico
- Volunteers
- 619 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab
The purpose of this study is to examine the relationship between anti-drug antibodies, serum drug concentrations, and clinical response for rheumatoid arthritis patients being treated with etanercept, adalimumab or infliximab.
- Trial name
- ANTIBODY-RA (NCT01981473)
- Testing
- no intervention
- Where
- 54 sites in United States, Argentina and 3 more
- Volunteers
- 605 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients
The purpose of this study is to determine if the use of sub-cutaneous (SC) abatacept provides any structural benefit in patients with rheumatoid arthritis who have failed prior use of TNF therapy.
- Trial name
- NCT01351480
- Testing
- abatacept
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Arthritis & Rheumatic Disease Specialties Research
Rheumatoid Arthritis
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and safety of GDC-0853 in participants with moderate to…
- Trial name
- NCT02833350
- Testing
- GDC-0853, Adalimumab, Folic Acid
- Where
- 150 sites in United States, Argentina and 9 more
- Volunteers
- 578 people
- Sponsor
- Genentech, Inc.
Arthritis, Rheumatoid
Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients
This study is to evaluate available local data in Iraqi patients with rheumatoid arthritis on Enbrel treatment with regards to the impact of Rheumatoid factor and Anti-cyclic citrullinated peptide using data from the Baghdad…
- Trial name
- NCT04428424
- Testing
- Enbrel
- Where
- Iraq
- Volunteers
- 1,493 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)
This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in combination with methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate.
- Trial name
- STAGE (NCT00406419)
- Testing
- Methotrexate, ocrelizumab
- Where
- United States
- Volunteers
- 1,015 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
An Open Label Study for Participants With Rheumatoid Arthritis
The primary purpose of this study is to help answer if LY2127399 is safe and effective during long-term treatment in participants with Rheumatoid Arthritis.
- Trial name
- NCT01215942
- Testing
- LY2127399
- Where
- 327 sites in United States, Argentina and 25 more
- Volunteers
- 1,086 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis (RA)
A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
The study objectives of Period 1 of this study were to compare the efficacy, safety, and tolerability of upadacitinib versus placebo for the treatment of signs and symptoms of subjects from China and selected countries including…
- Trial name
- NCT02955212
- Testing
- Upadacitinib
- Where
- 43 sites in Brazil, China and 1 more
- Volunteers
- 338 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)
This is a study of the overall safety, tolerability, and pharmacokinetics (PK) of MK-8808 versus rituximab (MabThera® and Rituxan®) in participants with moderate to severe RA with an inadequate response or intolerance to…
- Trial name
- NCT01390441
- Testing
- MK-8808, MabThera® (rituximab), Methotrexate
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients
The objectives of this study are to evaluate the safety and efficacy of certolizumab pegol as add-on medication to methotrexate over the long term in Japanese RA patients transferred from Study 275-08-001 (NCT00791999), and to…
- Trial name
- NCT00851318
- Testing
- Certolizumab pegol, Methotrexate
- Where
- 8 sites in Japan
- Volunteers
- 285 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis
Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China
The objective of this study was to assess the effectiveness of adalimumab on health and disability outcomes in participants with rheumatoid arthritis (RA) in China.
- Trial name
- NCT02668640
- Testing
- Adalimumab
- Volunteers
- 55 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
This is a multicenter, two-part, randomized, double-blind, placebo-kontrolled, 4-week study with repeated doses of AP1189. The study population will consist of newly diagnosed subjects with severe active Rheumatoid Arthritis…
- Trial name
- BEGIN (NCT04004429)
- Testing
- 50 mg AP1189, AP1189
- Where
- 2 sites in Denmark, Norway
- Volunteers
- 105 people
- Sponsor
- SynAct Pharma Aps
Rheumatoid Arthritis
Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
The purpose of this study is to establish proof of concept and identify the optimal efficacious dose for namilumab in RA in patients with an inadequate response to methotrexate (MTX-IR) and in patients with an inadequate response…
- Trial name
- NEXUS (NCT02379091)
- Testing
- Namilumab, Methotrexate, Folic/folinic acid
- Where
- 31 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 108 people
- Sponsor
- Takeda